OBJECTIVES: The purpose of this study was to describe rates and patterns of long- and short-acting alpha agonist use for behavioral problems in a primary care population following Food and Drug Administration (FDA) approval of the long-acting alpha agonists guanfacine and clonidine. METHODS: Children and adolescents 4-18 years of age, who received an alpha agonist prescription between 2009 and 2011, were identified from a sample of 45 United States primary care practices in two electronic health record-based research networks. Alpha agonist receipt was identified using National Drug Codes and medication names. The proportion of subjects receiving long- and short-acting prescriptions in each year was calculated and examined with respect to reported mental health diagnoses, and whether indications for use were on-label, had evidence from clinical trials, or had no trial evidence. RESULTS: In a cohort of 282,875 subjects, 27,671 (10%) received any psychotropic medication and only 4,227 subjects (1.5%) received at least one prescription for an alpha agonist, most commonly a short-acting formulation (83%). Only 20% of alpha agonist use was on-label (use of long-acting formulations for attention-deficit/hyperactivity disorder [ADHD]). Most subjects (68%) received alpha agonists for indications with evidence of efficacy from clinical trials but no FDA approval, primarily short-acting formulations for ADHD and autism; 12% received alpha agonists for diagnoses lacking randomized clinical trial evidence in children, including sleep disorders and anxiety, or for which there was no documented mental health diagnosis. Rates of long-acting alpha agonist use increased more than 20-fold from 0.2% to 4%, whereas rates of short-acting alpha agonist use grew only slightly between 2009 and 2011 from 10.6% to 11.3%. CONCLUSIONS: Alpha agonist use was uncommon in this population, and most subjects received short-acting forms for conditions that were off-label, but with clinical trial evidence. The safety and efficacy of use for conditions, including sleep disorders and anxiety, lacking evidence from randomized trials, warrant further investigation.
OBJECTIVES: The purpose of this study was to describe rates and patterns of long- and short-acting alpha agonist use for behavioral problems in a primary care population following Food and Drug Administration (FDA) approval of the long-acting alpha agonists guanfacine and clonidine. METHODS:Children and adolescents 4-18 years of age, who received an alpha agonist prescription between 2009 and 2011, were identified from a sample of 45 United States primary care practices in two electronic health record-based research networks. Alpha agonist receipt was identified using National Drug Codes and medication names. The proportion of subjects receiving long- and short-acting prescriptions in each year was calculated and examined with respect to reported mental health diagnoses, and whether indications for use were on-label, had evidence from clinical trials, or had no trial evidence. RESULTS: In a cohort of 282,875 subjects, 27,671 (10%) received any psychotropic medication and only 4,227 subjects (1.5%) received at least one prescription for an alpha agonist, most commonly a short-acting formulation (83%). Only 20% of alpha agonist use was on-label (use of long-acting formulations for attention-deficit/hyperactivity disorder [ADHD]). Most subjects (68%) received alpha agonists for indications with evidence of efficacy from clinical trials but no FDA approval, primarily short-acting formulations for ADHD and autism; 12% received alpha agonists for diagnoses lacking randomized clinical trial evidence in children, including sleep disorders and anxiety, or for which there was no documented mental health diagnosis. Rates of long-acting alpha agonist use increased more than 20-fold from 0.2% to 4%, whereas rates of short-acting alpha agonist use grew only slightly between 2009 and 2011 from 10.6% to 11.3%. CONCLUSIONS: Alpha agonist use was uncommon in this population, and most subjects received short-acting forms for conditions that were off-label, but with clinical trial evidence. The safety and efficacy of use for conditions, including sleep disorders and anxiety, lacking evidence from randomized trials, warrant further investigation.
Authors: Laurence L Greenhill; Steven Pliszka; Mina K Dulcan; William Bernet; Valerie Arnold; Joseph Beitchman; R Scott Benson; Oscar Bukstein; Joan Kinlan; Jon McClellan; David Rue; Jon A Shaw; Saundra Stock Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-02 Impact factor: 8.829
Authors: Dana D Cummings; Harvey S Singer; Madeline Krieger; Teresa L Miller; E Mark Mahone Journal: Clin Neuropharmacol Date: 2002 Nov-Dec Impact factor: 1.592
Authors: Daniel A Frattarelli; Jeffrey L Galinkin; Thomas P Green; Timothy D Johnson; Kathleen A Neville; Ian M Paul; John N Van Den Anker Journal: Pediatrics Date: 2014-02-24 Impact factor: 7.124
Authors: Susan Dosreis; Julie Magno Zito; Daniel J Safer; Karen L Soeken; John W Mitchell; Leslie C Ellwood Journal: J Dev Behav Pediatr Date: 2003-06 Impact factor: 2.225
Authors: Rafael E Perez; Aakash Basu; Bretton P Nabit; Nicholas A Harris; Oakleigh M Folkes; Sachin Patel; Ralf Gilsbach; Lutz Hein; Danny G Winder Journal: Neuropsychopharmacology Date: 2020-02-19 Impact factor: 7.853
Authors: Shannon G Panther; Alice M Knotts; Tamara Odom-Maryon; Kenneth Daratha; Teri Woo; Tracy A Klein Journal: J Pediatr Pharmacol Ther Date: 2017 Nov-Dec
Authors: Greta A Bushnell; Scott N Compton; Stacie B Dusetzina; Bradley N Gaynes; M Alan Brookhart; John T Walkup; Moira A Rynn; Til Stürmer Journal: J Clin Psychiatry Date: 2018 Jan/Feb Impact factor: 4.384
Authors: Jeffrey R Strawn; Scott N Compton; Brigitte Robertson; Anne Marie Albano; Mohamed Hamdani; Moira A Rynn Journal: J Child Adolesc Psychopharmacol Date: 2017-02-06 Impact factor: 2.576
Authors: Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle Journal: Neuropsychopharmacology Date: 2018-02-27 Impact factor: 7.853
Authors: Alexander G Fiks; Michelle E Ross; Stephanie L Mayne; Lihai Song; Weiwei Liu; Jennifer Steffes; Banita McCarn; Robert W Grundmeier; A Russell Localio; Richard Wasserman Journal: Pediatrics Date: 2016-11-15 Impact factor: 7.124